Skip to main content

Novo Holdings — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

216
Companies
$15.2B
Total invested
$84.4M
Avg. check
27
Industries
Biotechnology 19Health Care 15Medical 10Therapeutics 9Pharmaceutical 6Biopharma 5+21 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 216
Tarveda Therapeutics
September 2021

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

Biotechnology · Watertown$6.0M Venture - Series Unknown
Acesion Pharma
September 2023

Acesion Pharma is a developer of medical drugs designed for the treatment of atrial fibrillation.

Biotechnology · Frederiksberg$47.6M Series B
KalVista Pharmaceuticals
September 2025

KalVista Pharmaceuticals focuses on developing oral medicines, particularly for managing hereditary angioedema.

Biopharma · Cambridge$125.0M Post-IPO Debt
Kate Farms
September 2022

Kate Farms offers plant-based shakes and formulas for tube-fed adults and children.

Food and Beverage · Goleta$75.0M Series C
NeRRe Therapeutics
July 2021

NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.

Biotechnology · Stevenage$27.6M Series B
Biosyntia
July 2022

Biosyntia is a biotech startup within synthetic biology and metabolic engineering.

Biopharma · Hørsholm$11.7M Series B
Claris Biotherapeutics
July 2026

Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.

Biopharma · Jersey City$118.0M Series B
Inozyme
July 2023

Inozyme is a biopharmaceutical company developing therapeutics for rare diseases, with a focus on bone health.

Biotechnology · Boston$60.0M Post-IPO Equity
Aristea Therapeutics
July 2021

Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.

Biotechnology · San Diego$63.0M Series B
Crystalys Therapeutics
July 2026

Crystalys Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for gout and hyperuricemia.

Biopharma · San Diego$130.0M Series B
Asceneuron
July 2024

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

Biotechnology · Lausanne$100.0M Series C
Roslin Technologies
July 2026

Roslin Technologies is a biotechnology company that focuses on developing technologies for the agricultural and animal health sectors.

Agriculture · EdinburghGrant
INBRACE
July 2022

Swift Health Systems is a stealth stage start-up medical device company, developing INBRACE.

Consumer · Irvine$45.0M Debt Financing
Inspirna
July 2022

Inspirna is a biotechnology company developing drugs for the treatment of cancer.

Biotechnology · New York$55.1M Series D
AvenCell
June 2025

Based on our deep science and focused on patients in need.

Health Care · Watertown$40.0M Grant
The Protein Brewery
June 2026

The Protein Brewery specializes in developing and making animal-free-based protein in a sustainable way.

Biotechnology · Breda$20.5M Series B
Corwave
June 2023

CorWave is a medical device company developing innovative heart pumps.

Health Care · Paris$28.4M Series C
Tempus
May 2026

Tempus develops AI-enabled precision medicine technology that supports clinical decision-making and biomedical research.

Artificial Intelligence (AI) · Chicago$400.0M Post-IPO Debt
Windward Bio
May 2026

Windward Bio develops monoclonal antibodies for advanced immunological diseases.

Biotechnology · Basel$165.0M Series B
Morphic Therapeutic
May 2023

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

Biotechnology · Waltham$276.0M Post-IPO Equity
Engimmune Therapeutics
May 2022

Engimmune Therapeutics is a platform and product development company engineering next-generation T cell receptor therapies.

Biotechnology · Basel$15.8M Seed
CARGO Therapeutics
May 2024

CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.

Biotechnology · San Mateo$110.0M Post-IPO Equity
cAMPfield Therapeutics
May 2026

cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions.

Biopharma · San Diego$180.0M Series A
Mirum Pharmaceuticals
May 2026

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

Biotechnology · Foster City$600.0M Post-IPO Debt

Where Novo Holdings invests

Biotechnology19
Health Care15
Medical10
Therapeutics9
Pharmaceutical6
Biopharma5

About Novo Holdings's portfolio

How many companies has Novo Holdings invested in?

Novo Holdings has invested in 216 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Novo Holdings invest in?

Novo Holdings's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 27 different industry categories.

What is Novo Holdings's largest investment?

Among tracked funding rounds, Mirum Pharmaceuticals received $600.0M in a Post-IPO Debt round. Novo Holdings's total known invested capital is $15.2B.

What is the average investment size for Novo Holdings?

Novo Holdings's average investment size is $84.4M across its portfolio of 216 companies.

What are Novo Holdings's most recent investments?

Recent Novo Holdings portfolio additions include Tarveda Therapeutics, Acesion Pharma, KalVista Pharmaceuticals, Kate Farms, NeRRe Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 216 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →